New CAR-T manufacturing method could reduce cancer relapse rates Scientists have developed a new CAR-T manufacturing method using a multi-cytokine scaffold that produces longer-lived immune cells capable of self-renewal. Written byBree Foster, PhD

https://www.drugdiscoverynews.com/new-car-t-manufacturing-method-could-reduce-cancer-relapse-rates-17074?utm_campaign=DDN_Newsletter_Dose&utm_medium=email&_hsenc=p2ANqtz-8mvFHwD3BJIuPDuPiGIJWFszp_jF7C5RGNIx0kwiCd0z5jODQyEIRo5QzKIVYBEuqT-iuB02W7ijaiIH_0bwFcLekTsQ&_hsmi=427883198&utm_content=427883198&utm_source=hs_email For years, chimeric antigen receptor T cells — better known as CAR-T cells — have been heralded as a revolutionary form of “living drug.” By reprogramming a patient’s own immune cells to seek out and destroy cancer or virus-infected cells, CAR-T therapy can achieve remarkable initial remissions. Since the FDA approved tisagenlecleucel (Kymriah) in 2017 for the treatment of B-cell acute lymphoblastic leukemia, a total of seven CAR-T products — each targeting hematologic malignancies — have received FDA approval. These therapies have demonstrated remarkable clinical outcomes, including remission rates exceeding 80 percent in some cases.